an evaluation of in vitro and in vivo toxicity of chitosan-pdna polyplexes kae amaraporn the...
TRANSCRIPT
![Page 1: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/1.jpg)
An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexesKae Amaraporn
The Department of Pharmaceutics and Translational TherapeuticsCollege of Pharmacy
1
![Page 2: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/2.jpg)
Gene delivery to lung• The transmission of DNA encoding for therapeutic gene or
protein into the target cells for prevention or treatment of disease
• Potential treatment for • Cystic fibrosis, Asthma
• Advantages1. Easily accessible via airways
2. Large surface area for transfection
3. Reduces the risk of systemic side effects
• Disadvantages1. Repulsion between DNA & cell membrane due to same
charge
2. Enzymatic degradation 2
Mohammadi, Z., et al., In vivo transfection study of chitosan-DNA-FAP-B nanoparticles as a new non viral vector for gene delivery to the lung. Int J Pharm, 2011. 421(1): p. 183-8.Albelda, S.M., R. Wiewrodt, and J.B. Zuckerman, Gene therapy for lung disease: hype or hope? Ann Intern Med, 2000. 132(8): p. 649-60.
![Page 3: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/3.jpg)
Cationic polymers:DNA complex
• Storrie, H. and D.J. Mooney, Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Adv Drug Deliv Rev, 2006. 58(4): p. 500-14.
• Shan, Y., et al., Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials, 2012. 33(10): p. 3025-35.
3
![Page 4: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/4.jpg)
Bacterial plasmids
• Bacterial plasmids are circular DNA which can replicated independently of the bacterial chromosome.
• Bacterial DNA is rich in unmethylated CpGs • activate the immune system• induce inflammatory response (in vivo)• decrease transgene expression
• This study, we studied 2 types of pDNAs1. CpG(-) is a plasmid free of CpG
2. CpG(+) is a plasmid containing CpG
4
www.qiagen.com
![Page 5: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/5.jpg)
Objectives1. To characterized and optimized chitosan/pDNA
polyplex formulations1. Size and charge
2. Ability to condense plasmids
2. To investigate the toxicity and transfection efficiency in A549 and HEK293
1. MTS assay
2. Luciferase assay
3. To investigate the inflammatory response induced by the polyplexes in a mouse model
5
![Page 6: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/6.jpg)
Experiments and Results
6
![Page 7: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/7.jpg)
Objectives1. To characterized and optimized chitosan/pDNA
polyplex formulations1. Size and charge
2. Ability to condense plasmids
2. To investigate the toxicity and transfection efficiency in A549 and HEK293
1. MTS assay
2. Luciferase assay
3. To investigate the inflammatory response induced by the polyplexes in a mouse model
7
![Page 8: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/8.jpg)
Preparation of the chitosan/pDNA polyplex(+) charged polyelectrolyte was poured into (-) charged polyelectrolyte then vortexted for 20-30 s leading to the formation of the polyplexes
pDNA Dextransulfate
30 min
Chitosanin Acetate buffer CH/DS-pDNA
nanoplex
*pDNA 50 ug/ml *CH:DS = 10:1 (w/w)*Concentration of chitosan depends on N/P ratios
8
![Page 9: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/9.jpg)
Characterization
CH/CpG(-)
CH/CpG(+)
9
Size Charge
![Page 10: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/10.jpg)
Gel Retardation Assay
• 1% Agarose gel contains ethidium bromide loaded with CH/CpG(+) polyplexes.
• Chitosan can entrapped pDNA and inhibit DNA migration at N/P ratios > 1.
10
DN
Ala
dder
pDN
A N
/P 1
N/P
5
N/P
10
N/P
20
N/P
60
N/P
100
![Page 11: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/11.jpg)
Objectives1. To characterized and optimized chitosan/pDNA
polyplex formulations1. Size and charge
2. Ability to condense plasmids
2. To investigate the toxicity and transfection efficiency in A549 and HEK293
1. MTS assay
2. Luciferase assay
3. To investigate the inflammatory response induced by the polyplexes in a mouse model
11
![Page 12: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/12.jpg)
Cell lines• A549
• Human lung carcinoma
12
www.atcc.org
• HEK293• Human embryonic kidney
![Page 13: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/13.jpg)
Cationic polymers:DNA complex
• Storrie, H. and D.J. Mooney, Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Adv Drug Deliv Rev, 2006. 58(4): p. 500-14.
• Shan, Y., et al., Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors. Biomaterials, 2012. 33(10): p. 3025-35.
13
![Page 14: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/14.jpg)
Transfection efficiency
• Firefly luciferase activity assay • Firefly luciferase is
• 61kDa protein – cosubstrate to catalyzes luciferin oxidation
• sensitive assay to study gene expression
14
www.promega.com
![Page 15: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/15.jpg)
Transfection experiment
24-well plate
1 day
48 h
4 h0 h
CH/pDNA
PBS and RLB
24 h
15
Luciferase assay and Micro BCA assay
![Page 16: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/16.jpg)
Luciferase expressionCH/CpG(-) CH/CpG(+)
16
![Page 17: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/17.jpg)
MTS assay
• MTS is bioreduced by cells into formazan (color).• The quantity of formazan production is proportional to number
of living cells.
18
www.promega.com
![Page 18: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/18.jpg)
MTS assay
19
96-well plate
1 day
48 h
4 h0 h
CH/pDNA
MTSreagent
![Page 19: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/19.jpg)
Cytotoxicity assay: MTSCH/CpG(-) CH/CpG(+)
20
CH/CpG(-) CH/CpG(+)
![Page 20: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/20.jpg)
Objectives1. To characterized and optimized chitosan/pDNA
polyplex formulations1. Size and charge
2. Ability to condense plasmids
2. To investigate the toxicity and transfection efficiency in A549 and HEK293
1. MTS assay
2. Luciferase assay
3. To investigate the inflammatory response induced by the polyplexes in a mouse model
23
![Page 21: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/21.jpg)
In vivo study
24
CH/pDNA polyplexes
CH/pDNA polyplexes
1 h 24 h
BALfluid
C57Bl/6(n=6)
Supernatant from homogenized lung
• Luciferase assay • Micro BCA assay
• Total cell count• Total protein/LDH• Cytokines
![Page 22: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/22.jpg)
Luciferase expression in mice lungs
Mice treated with CH/CpG(-) shows highest luciferase expression.
25
Control
CH/CpG(-)
CH/CpG(+
)
Chitosa
n
CpG(+)
0
10000
20000
30000
40000
50000**
RL
U/m
g t
ota
l Pro
tein
![Page 23: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/23.jpg)
Number of cells in BAL fluids
26
• Mice treated with CH/CpG(-) shows maximum number of total cell count in BAL fluids.
• Among three types of white blood cells, BAL fluids contain high neutrophils in both types of polyplexes.
A
Control
CH/CpG(-)
CH/CpG(+
)
Chitosa
n
CpG(+)
0
500
1000
1500
2000**
To
tal n
um
ber
of
cells
/
Mo
use
x10
3
B
Control
CH/CpG(-)
CH/CpG(+
)
Chitosa
n
CpG(+)
0
20
40
60
80
100
120MacrophagesNeutrophilsLymphocytes
% o
f ce
lls f
rom
to
tal c
ells
![Page 24: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/24.jpg)
Total protein and LDH activity
27
![Page 25: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/25.jpg)
Cytokines
28
A. IL-6
B. IL-12
C. KC
D. MIP-1α
E. TNF-α
![Page 26: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/26.jpg)
Conclusion• Characteristic of Chitosan/pDNA polyplex
• size 100-170 r.nm• charge 20-30 mV
• CH/pDNA polyplex shows low cytoxicity in A549 and HEK293. There is no difference in toxicity between the nanoplex created using CpG(-) or CpG(+).
• The polyplex prepared from from CpG-free plasmids shows …• higher transgene expression in A549 and in mice lungs• less inflammation in vivo
• N/P ratio and DNA content of Chitosan/pDNA polyplex plays an important role in achieving high gene expression with minimal toxicity and inflammation.
29
![Page 27: An evaluation of in vitro and in vivo toxicity of chitosan-pDNA polyplexes Kae Amaraporn The Department of Pharmaceutics and Translational Therapeutics](https://reader035.vdocuments.mx/reader035/viewer/2022062515/56649f515503460f94c74476/html5/thumbnails/27.jpg)
Future work• To study lung histopathology of mice when treated
with the chitosan/pDNA polyplex• Lung abnormalities• Abnormal inflammatory infiltrates
• To develop chitosan/pDNA polyplex formulation which can form complex at high concentration and give high transfection efficiency
• To investigate the difference between nasal instillation and aerosol delivery
30